Lexeo Therapeutics, Inc. LXEO
3.31
(0.08)
(2.36%)
as of 25 Sep
- Market cap
- $278.3M
- P/E
- 0.0×
Follow LXEO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.11 | 10.81 | 13.61 | 13.49 | |
Current Ratio |
7.40 | 11.21 | 14.16 | 13.89 | |
Net Debt/EBITDA |
5.68 | 7.88 | 8.65 | 7.58 | |
Debt/Assets |
0.32% | 0.12% | 0.08% | 0.04% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.46 | 0.96 | 1.05 | 0.68 | |
Capex/Depreciation |
(2.17) | 0.00 | (1.13) | (0.07) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.48) | (0.37) | (0.26) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.49) | (0.37) | (0.26) | (0.21) | |
Cash per Share |
2.01 | 3.39 | 2.38 | 2.47 | |
Shareholders Equity per Share |
1.98 | 4.60 | 2.85 | 2.75 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.98 | 4.60 | 2.85 | 2.75 | |
Free Cash Flow |
(29.84) | (20.08) | (21.18) | (17.60) | |
Working Capital |
110.52 | 171.58 | 186.67 | 202.22 | |
Capital Expenditures |
(0.29) | 0.00 | (0.03) | (0.01) | |
Net Current Asset Value |
104.78 | 166.37 | 182.00 | 198.07 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
6.55 | 5.64 | 7.66 | 12.10 | |
Average Assets |
158.85 | 207.82 | 188.02 | 215.48 | |
Average Common Equity |
130.08 | 181.76 | 159.81 | 186.64 |
Columns are period end dates